Lilly and Resilience to Invest $750 Million in U.S. Drug Manufacturing Expansion
Eli Lilly (LLY) has partnered with contract manufacturer Resilience to invest $750 million in expanding pharmaceutical manufacturing capacity within the United States, aiming to strengthen domestic medicine supply chains. The investment is part of broader efforts by global drugmakers to increase U.S.-based production amid potential 100% tariffs on branded drugs under President Donald Trump's administration unless companies reduce prices or manufacture domestically. The partnership will create over 400 high-skilled jobs in the Cincinnati, Ohio region and expand manufacturing for critical medicines. Resilience noted that its operations now include producing Lilly’s KwikPen injectable device used to treat diabetes and obesity. The collaboration has already produced more than 150 million doses of medicine since it began in 2023. Lilly's U.S. capital expansion commitments total over $55 billion since 2020, with plans to break ground on several new manufacturing sites this year.
Tickers: $LLY
Topics: drug manufacturing investment tariffs U.S. supply chain